Article 29 referral: CMDh referral and CHMP arbitration in MRP and DCP

An Article 29 referral settles a disagreement between Member States in an MRP or DCP, first in the CMDh and, failing agreement, by CHMP arbitration.

Also known as: CMDh referral, Article 29(4) referral, Article 29(1) referral, arbitration

4 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Article 29 of Directive 2001/83/EC
Trigger
A CMS maintains a potential serious risk to public health at Day 90 (MRP) or Day 210 (DCP)
Timeline
60 days in the CMDh, then 60 days for the CHMP opinion
Outcome
Agreement recorded by the RMS, or a Commission decision

How it works

Article 29(1) of Directive 2001/83/EC applies when a Member State cannot approve the assessment report, summary of product characteristics, labelling and package leaflet in an MRP or DCP on grounds of potential serious risk to public health. It must explain its reasons in detail, and the points of disagreement are referred to the CMDh. The Commission's guideline of 2006 defines such a risk as a significant probability that a serious hazard from the product, in its proposed use, will affect public health, weighed against its therapeutic benefit. Objections of any other kind cannot block the procedure.

The first stage runs in the CMDh. The RMS refers the matter within seven days of Day 90 or Day 210, and the 60-day procedure normally starts within 30 days. The Member States agree a list of questions, which reaches the applicant by Day 10; the applicant answers by Day 25 and may present its case orally at a CMDh meeting. No new data are accepted, because there is no time to assess them. If the Member States agree, the RMS records the agreement and closes the procedure, at Day 150 of an MRP or Day 270 of a DCP, and national decisions follow within 30 days. The same CMDh procedure is used for disagreements on renewals, extensions, Type II variations and worksharing procedures.

If the CMDh cannot agree within 60 days, Article 29(4) sends the matter to the European Medicines Agency for the procedure in Articles 32 to 34, often called arbitration. The CHMP appoints a rapporteur and gives a reasoned opinion within 60 days; the further 90 days available in Article 30 and 31 referrals do not apply, although the clock can be suspended while the applicant prepares explanations. The Commission then adopts a decision that binds every Member State concerned. Under Article 29(6) the Member States that approved the RMS assessment may, at the applicant's request, authorise the product without waiting for the outcome.

The route has limits. If the RMS itself concludes that the product is not approvable, the procedure ends negatively and there is nothing to refer. For a generic, a concern that relates to the dossier of the reference product cannot start an Article 29 referral; an Article 30 or 31 referral is the route for that. Withdrawing the application from the objecting Member State does not prevent the referral in an MRP, or in a DCP after the draft assessment report has been circulated at Day 120, and only a withdrawal in every Member State ends it.

What goes wrong

Leaving a potential serious risk unresolved until the last days of the procedure and relying on a break-out session to settle it; preparing new studies for the CMDh stage, where they will not be accepted; withdrawing from the objecting country late and finding the referral goes ahead anyway; and forgetting to ask the agreeing Member States for authorisations under Article 29(6), which leaves the product off every market while the arbitration runs.

Timing

  1. Day 90 or Day 210

    CMS notifies a potential serious risk to public health with detailed reasons.

  2. Within 7 days

    RMS refers the points of disagreement to the CMDh.

  3. CMDh Day 10

    Agreed list of questions is sent to the applicant.

  4. CMDh Day 25

    Applicant's written response; no new data are accepted.

  5. CMDh Day 60

    Agreement recorded by the RMS, or the matter goes to EMA.

  6. Within 60 days

    CHMP opinion under Article 32, followed by a Commission decision.

The disagreeing Member State notifies its position by Day 90 of an MRP or Day 210 of a DCP, and the RMS refers the matter to the CMDh within seven days. The 60-day CMDh procedure normally starts within 30 days: list of questions to the applicant by Day 10, response by Day 25, updated RMS assessment report around Day 35, and agreement sought at a CMDh meeting before Day 60. Without agreement the RMS informs EMA the next day, and the CHMP gives its opinion within 60 days under Article 32(1). The Commission decision follows, and Member States act within 30 days of notification.

Article 29 referral: common questions

What is a potential serious risk to public health?

The Commission's 2006 guideline defines it as a significant probability that a serious hazard resulting from a medicine, in the context of its proposed use, will affect public health. It is judged against the product's benefits and can relate to efficacy, including proof of bioequivalence for a generic, to safety, to quality, to the overall benefit-risk balance or to misleading product information.

Can the product be authorised while CHMP arbitration is running?

Yes, in part. Under Article 29(6) of Directive 2001/83/EC, the Member States that approved the RMS assessment report and product information may authorise the product at the applicant's request, without waiting for the CHMP outcome. Those authorisations are without prejudice to the final decision. The option does not apply to variations and worksharing procedures.

Does withdrawing from the objecting Member State stop the referral?

Not usually. Under the CMDh procedure, withdrawal from a Member State that raised a potential serious risk to public health does not prevent the referral in an MRP, or in a DCP once the draft assessment report has been sent at Day 120. Only withdrawal of the application in all Member States ends the referral.

Sources

  1. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use, consolidated text
  2. EUR-Lex: Guideline on the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC (2006/C 133/05)
  3. CMDh: Disagreement in Procedures, Referral to CMDh, Standard Operating Procedure (CMDh/103/2005, Rev. 14, April 2022)
  4. CMDh: CMDh referrals, timetables and guidance

Put your Article 29 referral question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.